Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.

Yoon JH, Hong AR, Choi W, Park JY, Kim HK, Kang HC

Chonnam medical journal24 Sept 2021Cited by 5 (Europe PMC)

PMID34621642PMCIDPMC8485082DOI10.4068/cmj.2021.57.3.211PepBankPUB-34621642

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In Korean patients with diabetes, dulaglutide addition was linked to an adjusted HbA1c decrease of 1.13% from baseline.
In plain wordsAdding dulaglutide was linked to lower HbA1c than baseline in Korean patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c overall
Study
n = 112
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Adjusted HbA1c change from baseline
−1.13%
all patients, 6 months
Source sentences
Summary
The mean adjusted HbA1c at 6 months decreased by -1.13% in all patients (p<0.001), and by -1.36 and -0.74% in the OAD combination and basal insulin combination group, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
Report a problemFND-3462164201
02HumanObservational studyEfficacy outcome
In Korean patients with diabetes taking oral antidiabetic drugs, dulaglutide addition was linked to an HbA1c decrease of 1.36%.
In plain wordsAdding dulaglutide to oral drugs was linked to lower HbA1c than baseline in Korean patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c with oral antidiabetic drugs
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Adjusted HbA1c change from baseline
−1.36%
OAD combination group, 6 months
Source sentences
Summary
The mean adjusted HbA1c at 6 months decreased by -1.13% in all patients (p<0.001), and by -1.36 and -0.74% in the OAD combination and basal insulin combination group, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
Report a problemFND-3462164202
03HumanObservational studyEfficacy outcome
In Korean patients with diabetes taking basal insulin, dulaglutide addition was linked to an HbA1c decrease of 0.74%.
In plain wordsAdding dulaglutide to basal insulin was linked to lower HbA1c than baseline in Korean patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c with basal insulin
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Adjusted HbA1c change from baseline
−0.74%
basal insulin combination group, 6 months
Source sentences
Summary
The mean adjusted HbA1c at 6 months decreased by -1.13% in all patients (p<0.001), and by -1.36 and -0.74% in the OAD combination and basal insulin combination group, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
Report a problemFND-3462164203
04HumanObservational studyEfficacy outcome
In Korean patients with diabetes, dulaglutide addition was linked to a body weight decrease of 2.9 kg from baseline.
In plain wordsAdding dulaglutide was linked to lower weight than baseline in Korean patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 112
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Body weight change from baseline
−2.9 kg
all patients, 6 months
Source sentences
Summary
A significant reduction of -2.9 kg in body weight was observed in all patients at 6 months (p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
Report a problemFND-3462164204
05HumanObservational studyEfficacy outcome
In Korean patients with diabetes receiving dulaglutide, approximately 34.8% achieved HbA1c below 7.0%.
In plain wordsApproximately 34.8% of Korean patients with diabetes receiving dulaglutide reached HbA1c below 7.0%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c below 7.0%
Study
n = 112
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Patients achieving HbA1c <7.0%
≈ 34.8%
all patients
Source sentences
Summary
Approximately 34.8% and 23.2% of patients achieved HbA1c <7.0% and ≤6.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
Report a problemFND-3462164205
06HumanObservational studyEfficacy outcome
In Korean patients with diabetes receiving dulaglutide, approximately 23.2% achieved HbA1c at most 6.5%.
In plain wordsApproximately 23.2% of Korean patients with diabetes receiving dulaglutide reached HbA1c at most 6.5%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c at most 6.5%
Study
n = 112
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Patients achieving HbA1c <=6.5%
≈ 23.2%
all patients
Source sentences
Summary
Approximately 34.8% and 23.2% of patients achieved HbA1c <7.0% and ≤6.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
Report a problemFND-3462164206
07HumanObservational studySafety outcome
In Korean patients with diabetes receiving dulaglutide, mild gastrointestinal issues occurred in 23.2%.
In plain wordsMild digestive problems affected 23.2% of Korean patients with diabetes receiving dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableMild gastrointestinal adverse events
Study
n = 112
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Mild gastrointestinal adverse events
23.2%
all patients
Source sentences
Summary
Mild gastrointestinal issues (23.2%) were the most frequently observed adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
Report a problemFND-3462164208

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Korean patients with diabetes, higher baseline HbA1c and no previous insulin therapy were associated with positive responses to dulaglutide on multivariate analysis.
In plain wordsHigher starting HbA1c and no earlier insulin use were linked to a better response to dulaglutide in Korean patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePredictors of positive response to dulaglutide
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Higher baseline HbA1c and no previous insulin therapy were associated with positive responses to dulaglutide on multivariate analysis.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Summary · context
We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3462164207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.